NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) rose 9.2% to $3.80 after the company disclosed that its Auriclosene has met primary endpoint in Phase 2b trial. Share volume was 102,000, compared to an all-day average of 120,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
